HR 4623 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.
Summary
This bill requires the Centers for Medicare & Medicaid Services to issue regulations within one year mandating that direct-to-consumer television advertisements for prescription drugs and biological products covered by Medicare or Medicaid include a text statement showing the list price for a typical 30-day treatment regimen. The price shown must be current as of the first day of the quarter when the advertisement airs and must be truthful and not misleading. The agency will also determine whether the requirement should apply to other forms of advertising and whether additional price information should be included.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
4 cosponsors
- Rep. Bacon, Don [R-NE-2] (R-NE)
- Rep. Barrett, Tom [R-MI-7] (R-MI)
- Rep. Craig, Angie [D-MN-2] (D-MN)
- Rep. Steil, Bryan [R-WI-1] (R-WI)
Money behind the sponsor
Top reported contributors to Nikema Williams’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- RADCO $6,600
- PERENNIAL PROPERTIES $6,600
- GOLDMAN SACHS $6,600
- CORNERSTONE GOVERNMENT AFFAIRS $6,500
- NULL $6,300
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Nikema Williams → · Outside spending →
Actions (2)
- Jul 22, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Jul 22, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
July 22, 2025
Ms. Williams of Georgia (for herself, Mr. Bacon, Ms. Craig, and Mr. Steil) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Plain Prescription Prices Act”.
SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIPTION DRUG AND BIOLOGICAL PRODUCT PRICES.
(a) In General.—Not later than one year after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the “Administrator”), shall promulgate regulations requiring each direct-to-consumer advertisement on television (including broadcast, cable, streaming, and satellite television) for a prescription drug or biological product for which payment is available under title XVIII or XIX of the Social Security Act to include a textual statement, which shall be truthful and not misleading, indicating the list price, as determined on the first day of the quarter during which the advertisement is being aired or otherwise broadcast, for a typical 30-day regimen or typical course of treatment (whichever is most appropriate).
(b) Determinations.—In promulgating regulations under subsection
(a), the Administrator shall determine—
(1) whether such regulations should apply with respect to additional forms of advertising;
(2) the manner and format of textual statements described in such subsection;
(3) appropriate enforcement mechanisms; and
(4) whether such textual statements should include any other price information, as appropriate. <all>
Comments